Showing 881 - 900 results of 31,986 for search '(( 5 ((fold decrease) OR (point decrease)) ) OR ( 100 ((nn decrease) OR (a decrease)) ))', query time: 0.95s Refine Results
  1. 881
  2. 882
  3. 883
  4. 884
  5. 885
  6. 886
  7. 887
  8. 888
  9. 889

    Table 1_Atractylenolide-I restore intestinal barrier function by targeting the S100A9/AMPK/mTOR signaling pathway.xlsx by Chen Chen (6544)

    Published 2025
    “…Mechanistically, recombinant human S100A9 protein was found to induce a decrease in intracellular Ca<sup>2+</sup> concentration, while AT-1 regulated the expression of tight junction proteins via modulation of the AMPK/mTOR signaling pathway. …”
  10. 890

    Image 2_Atractylenolide-I restore intestinal barrier function by targeting the S100A9/AMPK/mTOR signaling pathway.tif by Chen Chen (6544)

    Published 2025
    “…Mechanistically, recombinant human S100A9 protein was found to induce a decrease in intracellular Ca<sup>2+</sup> concentration, while AT-1 regulated the expression of tight junction proteins via modulation of the AMPK/mTOR signaling pathway. …”
  11. 891

    Image 1_Atractylenolide-I restore intestinal barrier function by targeting the S100A9/AMPK/mTOR signaling pathway.tif by Chen Chen (6544)

    Published 2025
    “…Mechanistically, recombinant human S100A9 protein was found to induce a decrease in intracellular Ca<sup>2+</sup> concentration, while AT-1 regulated the expression of tight junction proteins via modulation of the AMPK/mTOR signaling pathway. …”
  12. 892
  13. 893
  14. 894

    Decreased self-renewal capacity associated with senescence was prevented in human MSCs following treatment with Ki16425, an LPA<sub>1</sub>/LPA<sub>3</sub> antagonist. by Masahiko Kanehira (183764)

    Published 2012
    “…Human MSCs at passage 2 were cultured in the presence or absence of Ki16425 for the indicated days prior to cell lysis. Fold-change represents decrease in band intensity of Ki16425 treatment for 18 days compared with a control treatment for the same period of time. …”
  15. 895
  16. 896
  17. 897
  18. 898
  19. 899

    Pharmacodynamic Profile of CCX168 in Healthy Human Volunteers. by Pirow Bekker (392139)

    Published 2016
    “…CD11b upregulation was diminished in both blood samples from CCX168 subjects with a 10-fold decrease in C5a potency exhibited in the 12-hour samples.…”
  20. 900